Brief: 3D Medicines Says License Agreement With Alphamab And Glenmark For Envafolimab
25/01/2024 01:11
Jan 25 (Reuters) - 3D Medicines Inc 1244.HK :
* LICENSE AGREEMENT WITH ALPHAMAB AND GLENMARK FOR
ENVAFOLIMAB
Further company coverage: 1244.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 3D Medicines
See all newsBrief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Brief: 3D Medicines Inc Says Zhang Jing Resigns As CFO
Brief: 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
Brief: 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Brief: 3D Medicines Inc Enters Strategic Agreement With Catug Biotechnology